R
Ronald H. Goldfarb
Researcher at University of North Texas Health Science Center
Publications - 86
Citations - 3459
Ronald H. Goldfarb is an academic researcher from University of North Texas Health Science Center. The author has contributed to research in topics: Natural killer cell & Interleukin 2. The author has an hindex of 26, co-authored 86 publications receiving 3351 citations. Previous affiliations of Ronald H. Goldfarb include University of Pittsburgh & University of North Texas.
Papers
More filters
Journal ArticleDOI
The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions.
Bruce S. McEwen,Christine A. Biron,Kenneth W. Brunson,Karen Bulloch,William H. Chambers,Firdaus S. Dhabhar,Ronald H. Goldfarb,Richard P. Kitson,Andrew H. Miller,Robert L. Spencer,Jay M. Weiss +10 more
TL;DR: This work presents a meta-anatomy of the adrenal gland and its role in the development and management of disease and urges further investigation into the role of “cell reprograming” and “reconcretization” in the course of disease progression.
Journal ArticleDOI
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
TL;DR: A novel dipeptidyl proteasome inhibitor, CEP1612, at low concentrations rapidly induces apoptosis in human Jurkat T cells overexpressing Bcl-2 and also in all human prostate, breast, tongue and brain tumor cell lines the authors have tested to date, without exception.
Journal ArticleDOI
NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
Per Albertsson,Per H. Basse,Marianne Hokland,Ronald H. Goldfarb,J. Fred Nagelkerke,Ulf Nannmark,Peter J. K. Kuppen +6 more
TL;DR: New insights into the migration of NK cells, their activation status and production of matrix-degrading proteases might help to overcome this localization defect, with implications for the treatment of human cancer.
Journal ArticleDOI
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
TL;DR: Recent experimental evidence obtained using inhibitors of uPA and uPAR has validated this system as a therapeutic target for the development of anti-angiogenic and anti-metastatic therapeutic agents.
Journal ArticleDOI
Immediate early detection of urokinase receptor after partial hepatectomy and its implications for initiation of liver regeneration
Wendy M. Mars,Meng-Lun Liu,Richard P. Kitson,Ronald H. Goldfarb,Megan K. Gabauer,George K. Michalopoulos +5 more
TL;DR: The de novo appearance of active uPA in livers from male Fischer F344 rats that underwent 70% partial hepatectomy (PHx) is documented, implying that both uPA and uPAR are involved in activating endogenous HGF in the regenerating livers of animals that underwent PHx.